Pacific Biosciences of California PACB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128.58M+80.5% | -$546.38M-75.0% | -$506.01M-28.3% | -$528.73M-32.1% | -$660.12M-122% | ||
| $10.06M-35.8% | $12.99M-5.7% | $13.09M-5.9% | $14.83M+17.5% | $15.67M+31.1% | ||
| $36.93M-39.2% | $41.67M-41.3% | $48.11M-32.8% | $55.39M-24.1% | $60.71M-17.6% | ||
| —— | —— | —— | —— | -$751K— | ||
| $0— | $15M— | —— | —— | —— | ||
| —— | —— | —— | -$176K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$315K— | $2.48M— | $4.39M— | -$2.49M— | —— | ||
| $3.16M— | $3.16M— | —— | —— | —— | ||
| -$2.8M— | -$8.51M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.19M-483% | -$1.69M-369% | $174K-76.0% | $271K-62.7% | $312K-69.4% | ||
| —— | —— | —— | —— | -$2.38M+74.3% | ||
| $4.08M-98.9% | $369.45M+1,248% | $375.28M+1,269% | $381.12M+1,673% | $386.95M+2,500% | ||
| $3.57M-69.0% | $3.98M-67.3% | $4.34M-66.1% | $8.47M-9.3% | $11.5M+59.7% | ||
| $3.77M+134% | $723K+106% | -$3.33M+71.3% | -$8.9M+5.2% | -$11.16M-21.8% | ||
| $0+100% | -$18.7M-2,100% | -$20.65M-1,039% | -$19.48M-2,667% | -$19.48M-813% | ||
| -$111.84M+35.9% | -$111.21M+46.0% | -$122.79M+47.3% | -$149.55M+40.8% | -$174.43M+27.4% | ||
| $4.45M— | $2.8M— | $3.56M— | —— | —— | ||
| $207.54M-43.7% | $216.91M-56.5% | $264.29M-57.4% | $313.06M-46.3% | $368.55M-48.5% | ||
| -$65.19M— | $0— | $26.8M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $5M— | ||
| $106.07M-47.8% | $115.45M-6.9% | $147.66M— | $151.82M— | $203.37M— | ||
| -$522K-127% | $0— | $3.43M— | $1.96M— | $1.96M— | ||
| —— | —— | —— | —— | -$47.58M— | ||
| -$2.87M— | $7.67M— | -$21.91M— | -$45.16M— | —— | ||
| —— | $8.26M-44.2% | $9.9M-34.1% | $11.53M-24.3% | $13.17M-14.8% | ||
| $4.08M-98.9% | $369.45M+1,248% | $375.28M+1,269% | $381.12M+1,673% | $386.95M+2,500% | ||
| $0+100% | -$18.7M-2,100% | -$20.65M-1,039% | -$19.48M-2,667% | -$19.48M-813% | ||
| $10.06M-35.8% | $12.99M-5.7% | $13.09M-5.9% | $14.83M+17.5% | $15.67M+31.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $38.6M-66.7% | $77.2M0.0% | $115.81M+200% | ||
| $3.77M+134% | $723K+106% | -$3.33M+71.3% | -$8.9M+5.2% | -$11.16M-21.8% | ||
| -$2.8M— | -$8.51M— | —— | —— | —— | ||
| $2.16M-82.7% | $9.77M+102% | $10.67M+8.7% | $9.45M-7.5% | $12.48M+76.6% | ||
| $2.95M-72.4% | $4.37M-66.5% | $6.29M-53.1% | $8.45M-40.9% | $10.72M-27.2% | ||
| $3.57M-69.0% | $3.98M-67.3% | $4.34M-66.1% | $8.47M-9.3% | $11.5M+59.7% | ||
| -$1.19M-483% | -$1.69M-369% | $174K+112% | $271K+119% | $312K+128% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $5M— | ||
| $274.88M-49.6% | $340.07M-42.7% | $393.62M-36.4% | $437.8M-46.0% | $545.76M-28.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $12.55M-66.7% | $25.1M0.0% | $37.65M+200% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.38M+74.3% | ||
| $3.77M+134% | $723K+106% | -$3.33M+71.3% | -$8.9M+5.2% | -$11.16M-21.8% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| -$116.21M+34.8% | -$113.92M+46.3% | -$126.26M+47.3% | -$152.32M+41.6% | -$178.13M+28.5% | ||
| -$116.21M+34.8% | -$113.92M+46.3% | -$126.26M+47.3% | -$152.32M+41.6% | -$178.13M+28.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacific Biosciences of California generate?
- Pacific Biosciences of California (PACB) generated -$111.8M in operating cash flow over the trailing twelve months.
- What is Pacific Biosciences of California's free cash flow?
- After $4.5M of capital expenditures, Pacific Biosciences of California's free cash flow was -$116.2M over the trailing twelve months, up 34.8% year over year.
- Where does Pacific Biosciences of California's cash flow data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
